

## CONTENTS

### VOLUME XI

<b>Bio-Cultural Diversity and Medicine</b>	<b>1</b>
Edgar J. DaSilva, <i>International Scientific Council for Island Development, France</i>	
Pier Giovanni d'Ayala, <i>Secretary-General, INSULA</i>	
Murukesan V. Krishnapillai, <i>College of Micronesia-FSM, Colonia, Yap, Federated States of Micronesi</i>	

1. Introduction
2. Biocultural diversity
  - 2.1. Africa
  - 2.2. Arab States
  - 2.3. Asia
  - 2.4. Europe
  - 2.5. Latin America and the Caribbean
  - 2.6. The Pacific Region
3. Socio-economic Diversity
  - 3.1. Africa
  - 3.2. Arab States
  - 3.3. Asia
  - 3.4. Europe
  - 3.5. Latin America and the Caribbean
  - 3.6. The Pacific Region
4. Conclusion

<b>Blood: The Essence of Humanity</b>	<b>31</b>
Sunil J. Parekh, <i>Hematology Laboratory, India</i>	
Shilpa Mehta, <i>Hematology Laboratory, India</i>	
Edgar J. DaSilva, <i>International Scientific Council for Island Development, France</i>	

1. Introduction
2. Blood Composition and Functions
  - 2.1. Red Blood Cells (Erythrocytes)
  - 2.2. White Blood Cells (Leukocytes)
  - 2.3. Platelets (Thrombocytes)
  - 2.4. Plasma
  - 2.5. Blood Components in Diagnosis of Diseases
3. Blood Groups
  - 3.1. Blood group systems
  - 3.2. ABO and Rh Blood Group System
  - 3.3. ABO and Rh Grouping Methods
    - 3.3.1. Forward Grouping
    - 3.3.2. Reverse Grouping
    - 3.3.3. Cross Matching
    - 3.3.4. Direct Coombs (Antiglobulin) Test (DCT)
    - 3.3.5. Indirect Coombs (Antiglobulin) Test (ICT)
4. Blood Transfusion - Safety and Transmission of Diseases
  - 4.1. Safety in Blood Transfusion
  - 4.2. Pre-donation considerations
  - 4.3. Adverse Effects of Blood Transfusion
    - 4.3.1. Transfusion Reactions
    - 4.3.2. Transfusion-Associated Graft versus Host Disease (TA-GvHD)
    - 4.3.3. Transfusion-Related Acute Lung Injury (TRALI)
  - 4.4. Blood Component Therapy

- 4.4.1. Collection of Blood for Transfusion
- 4.4.2. Preparation of red cells
- 4.4.3. Preparation of plasma
- 4.4.4. Preparation of cryoprecipitate
- 4.4.5. Preparation of platelet concentrate
- 4.4.6. Preparation of apheresis platelets
- 4.4.7. Plasma derivatives
- 4.5. Blood doping
- 5. Red Cell Indices and Morphology in Disease Diagnosis
  - 5.1. Red Cell Indices
  - 5.2. Morphology of Red Cells
    - 5.2.1. Size
    - 5.2.2. Shape
    - 5.2.3. Color
    - 5.2.4. Inclusions
    - 5.2.5. Nucleated Red Cells
  - 5.3. Red Cell Indices in Diagnosis
  - 5.4. Reticulocytes and their Importance
- 6. Anemias
  - 6.1. Iron Deficiency Anemia
    - 6.1.1. Stages of Iron Deficiency
    - 6.1.2. Causes of Iron deficiency are:
    - 6.1.3. Symptoms and Signs of Iron deficiency are:
    - 6.1.4. Treatment of Iron deficiency
  - 6.2. Thalassemias
  - 6.3. Sickle Cell Anemia
  - 6.4. Sideroblastic Anemia
  - 6.5. Megaloblastic Anemia
  - 6.6. Hemolytic Anemias
  - 6.7. G6PD Deficiency
- 7. Leukemias
  - 7.1. Acute Leukemias
    - 7.1.1. Acute myeloid leukemia (AML)
    - 7.1.2. Acute lymphoid leukemia (ALL)
    - 7.1.3. Clinical Features in AML and ALL
  - 7.2. Chronic Leukemias
    - 7.2.1. Clinical features in CML and CLL
    - 7.2.2. Hairy Cell Leukemia (HCL)
- 8. Bleeding and Clotting Disorders
  - 8.1. Bleeding Disorders
    - 8.1.1. Hemophilia
    - 8.1.2. Von Willebrands Disease (vWD)
  - 8.2. Clotting Disorders
- 9. Blood Parasites
  - 9.1. Malaria
    - 9.1.1. Types of Malaria
    - 9.1.2. Life Cycle of Malarial Parasite
    - 9.1.3. Clinical Features of Malaria
    - 9.1.4. Complications of Plasmodium Infections
  - 9.2. Filariasis
  - 9.3. Kala-Azar
  - 9.4. Trypanosomiasis
- 10. Blood Substitutes
  - 10.1. Red blood cell substitutes
- 11. Blood and the Arts
- 12. Conclusion

1. Introduction
2. Classes of fungi that are of Medical Interest
  - 2.1. Basidiomycetes
  - 2.2. Zygomycetes
  - 2.3. Ascomycetes
  - 2.4. Mitosporic fungi (Fungi imperfecti)
    - 2.4.1. Blastomycetes
    - 2.4.2. Coelomycetes
    - 2.4.3. Hyphomycetes
3. Clinical groupings of fungal infections
  - 3.1. Superficial infections
    - 3.1.1. Pityriasis versicolor
    - 3.1.2. Tinea nigra
    - 3.1.3. Black piedra
    - 3.1.4. White piedra
  - 3.2. Cutaneous infections
    - 3.2.1. Dermatophytosis (Ringworm and Tinea)
      - 3.2.1.1. Tinea capitis
      - 3.2.1.2. Tinea corporis
      - 3.2.1.3. Tinea cruris
      - 3.2.1.4. Tinea pedis
      - 3.2.1.5. Tinea manuum
      - 3.2.1.6. Tinea unguium
    - 3.2.2. Thrush
4. Subcutaneous infections
  - 4.1. Chromoblastomycosis
  - 4.2. Eumycotic Mycetoma
  - 4.3. Phaeohyphomycosis
  - 4.4. Hyalohyphomycosis
  - 4.5. Sporotrichosis
  - 4.6. Subcutaneous Zygomycosis
    - 4.6.1. Mucormycosis
    - 4.6.2. Entomophthoromycosis
5. Systemic infections
  - 5.1. Aspergillosis
  - 5.2. Cryptococcosis
  - 5.3. Zygomycosis
  - 5.4. Candidiasis
  - 5.5. Pseudallescheriasis
  - 5.6. Histoplasmosis
  - 5.7. Blastomycosis
  - 5.8. Coccidiomycosis
  - 5.9. Paracoccidiomycosis
6. Miscellaneous fungal or fungal-like diseases
  - 6.1. Rhinosporidiosis
  - 6.2. Lobomycosis
  - 6.3. Protothecosis
  - 6.4. Pythiosis
7. Antifungal Therapy
  - 7.1. Commonly used Antifungal agents
    - 7.1.1. Amphotericin B
    - 7.1.2. Fluconazole
    - 7.1.3. Itraconazole
    - 7.1.4. Voriconazole
    - 7.1.5. Posaconazole

- 7.1.6. Caspofungin
- 7.1.7. Nystatin
- 7.1.8. Terbinafine and antifungals containing the 'allyl' group
- 7.1.9. Topical antifungals
- 7.2. In vitro Sensitivity Testing Procedures
- 8. Identification of fungi- The Classical Approach to Fungal Identification
  - 8.1. The steps involved in identifying a microfungus
    - 8.1.1. Macroscopic inspection after isolation on relevant media
      - 8.1.1.1. Yeasts
      - 8.1.1.2. Moulds
    - 8.1.2. Microscopic inspection
- 9. Serological testing

### **Lysine Biosynthesis In Bacteria – An Uncharted Pathway For Novel Antibiotic Design 116**

Con Dogovski, Sarah C. Atkinson, Sudhir R. Dommaraju, Renwick C. J. Dobson, and Matthew A. Perugini, *Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia*  
 Lilian Hor, *Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia*  
 School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia  
 Craig A. Huton, *School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia*  
 Juliet A. Gerrard, *School of Biological Sciences, University of Canterbury, Christchurch, New Zealand*

1. Introduction
2. Lysine Biosynthesis Pathway in Bacteria
3. Identification and Validation of Targets
4. Dihydrodipicolinate Synthase [DHDPS]
  - 4.1. Function of DHDPS
  - 4.2. Structure of DHDPS
  - 4.3. Inhibition of DHDPS
5. Dihydrodipicolinate Reductase [DHDPR]
  - 5.1. Function of DHDPR
  - 5.2. Structure of DHDPR
  - 5.3. Inhibition of DHDPR
6. Diaminopimelate (DAP) Epimerase
  - 6.1. Function of DAP epimerase
  - 6.2. Structure of DAP epimerase
  - 6.3. Inhibition of DAP epimerase
7. Conclusions

### **Antibody Based Protein Research In Human Pathology 137**

C. Gulmann, C. Buckley, *Departments of Histopathology, Beaumont Hospital, Dublin, Ireland*  
 R. Cummins, *Royal College of Surgeons, Dublin, Ireland*

1. Introduction
  - 1.1. Antigen-Antibody Interactions
2. Routine Antibody Based Methods in Pathology
  - 2.1. Immunohistochemistry in Histological Material
    - 2.1.1. Principles and History
    - 2.1.2. Antibodies
    - 2.1.3. Blocking Non-Specific Background
    - 2.1.4. Detection Systems
    - 2.1.5. Tissue Fixation, Processing and Antigen Retrieval
  - 2.2. Flow Cytometry

- 2.3. Fluorescent Techniques
  - 2.3.1. Immunofluorescence
  - 2.3.2. ELISA
3. Novel Protein Investigation Techniques
  - 3.1. Protein Array Techniques
    - 3.1.1. Antibody Arrays
    - 3.1.2. 'Reverse Phase Arrays'
  - 3.2. Ancillary Methods in Protein Arrays
    - 3.2.1. Antibody Validation
    - 3.2.2. Tissue Microdissection
    - 3.2.3. Large Scale Validation – The Role of Tissue Microarrays
    - 3.2.4. Data Analysis of Large Data Sets
4. Problems in Antibody Based Methods
  - 4.1. Procurement of 'Specific' Antibodies
  - 4.2. Standardisation
  - 4.3. Increasing Throughputness
5. Conclusions

### **Integrated Thermo-Biorefinery**

154

Michael Theroux, *Theroux Environmental, California, USA*

1. Introduction
2. Priorities of Waste Management and Resource Recovery
3. Secondary Recycling via Thermal Recovery
4. Feedstock Considerations
5. Thermal Technology Energetics
  - 5.1. Pre-combustion physical reaction stage
  - 5.2. Mass-burn incineration
  - 5.3. Devolatilization
    - 5.3.1. Primary stage pyrolysis
    - 5.3.2. Secondary stage pyrolysis
  - 5.4. Gasification
    - 5.4.1. Allothermal gasification
    - 5.4.2. Autothermal gasification
  - 5.5. Plasma gasification
  - 5.6. Reforming
6. Optimal Thermo-Biorefinery Campus Design
  - 6.1. Heat-first design
  - 6.2. Electricity-first design
  - 6.3. Combined heat and power (CHP)
  - 6.4. Biofuel-first design
  - 6.5. CCHP + Fuels
  - 6.6. The case for multi-path, multi-technology integration
7. Establishing a "Bright Line"
8. External Technology Validation
9. Conclusion

### **The Role of Phytobiotechnology in Public Health**

187

Kenneth Anchang Yongabi, *Phytobiotechnology Research Foundation and Clinic, Bamenda, Cameroon*

1. Introduction: The Concept of Medicinal Plants and Phytobiotechnology
2. A Recap of Infectiology and Contemporary Challenges in the Control of Infectious Diseases
  - 2.1. Challenges involved in Controlling Infectious Diseases
  - 2.2. Synthetic Antibiotics in Health Care and their Shortfalls
  - 2.3. Applications of Medicinal Plant Biotechnology in the Control of Leishmaniasis and Dracunculiasis, Case Study: Northern Nigeria

- 2.4. Medicinal Plants and Medicinal Plant Biotechnology in the Control of Mosquitoes (*Anopheles*) and Houseflies (*Musca Domestica*) in the Tropics
3. Medicinal Plants and Macrofungi in Control of Fungal Infections and Other Dermatological Problems
4. Employing Appropriate Medicinal Plant Biotechnology in the Management of HIV/AIDS And Cancer
  - 4.1. Role of Medicinal Plant Biotechnology in the Treatment of Cardiac and Neurological, Central Nervous System Disorder, Rheumatic Arthritis Etc
  - 4.2. Management Of Hepatitis, Cancers And Autoimmune Disorders Using Medicinal Plant Extracts
5. Medicinal Plant Biotechnology in Preventive Health
  - 5.1. Exploiting the Potentials of African Medicinal Plants and Indigenous Knowledge in Environmental Sanitation and Hygiene: Water Purification With Phytocoagulants
  - 5.2. A Preliminary Study on Disinfection of Fresh Human Excrements with Medicinal Plant Seeds, Kerosene and Saw Dust
6. Conclusions

### Medical Biotechnology-Modern Development

218

Tan Min Chin, *National University Hospital, Singapore*

Felicia Su Wei Teo, *Singapore General Hospital, Singapore*

Li Yang Hsu, *National University Hospital, Singapore*

1. Introduction
2. Diagnostics
  - 2.1. Nucleic Acid Tests
    - 2.1.1. Role in Infectious Diseases
    - 2.1.2. Role in Cancer
    - 2.1.3. Prenatal Screening and Pre-implantation Genetic Diagnosis
  - 2.2. Monoclonal Antibodies
  - 2.3. Proteomics for Diagnostics
  - 2.4. Nanodiagnostics
3. Therapeutics
  - 3.1. rDNA Drugs and Vaccines
    - 3.1.1. Bio-factories
    - 3.1.2. Efficacy and Adverse Effects
  - 3.2. Gene Therapy
    - 3.2.1. History and Development
    - 3.2.2. Barriers
  - 3.3. Stem Cells
  - 3.4. Rational Drug Design
4. Economics and Industry Trends
  - 4.1. Medical Biotechnology Market
  - 4.2. Industry Strategies
  - 4.3. Financing
  - 4.4. Market Forces and Beneficiaries
5. Regulation
  - 5.1. Drug Approval
  - 5.2. Research Regulation and Patents
6. Social Issues and Ethics
  - 6.1. Stem Cell Research
  - 6.2. Cloning
  - 6.3. Genetic Testing and Therapy
  - 6.4. Genetic Databases
  - 6.5. Health Inequities
7. Conclusion

**Bioinformatics on Post Genomic Era-> From Genomes to Systems Biology****240**Mauno Vihinen, *University of Tampere, Finland*

1. Introduction
  - 1.1. Implications of Genomes
2. Bioinformatics and Internet
3. Genomes
4. Databases
  - 4.1. Annotation
  - 4.2. Gene ontologies
  - 4.3. Data Mining
5. Sequence Alignment
6. Common Sequence Analysis Methods
  - 6.1. Gene Finding
  - 6.2. Mapping
  - 6.3. DNA/RNA Secondary Structure
  - 6.4. Primer Selection
  - 6.5. Translation
  - 6.6. Protein Analysis
  - 6.7. Pattern Searches
7. Functional Genomics
  - 7.1. Gene and Protein Expression
8. Protein Structure Predictions
9. Systems biology
10. Trends and Prospects

**Gene Therapy****253**

Mikko Laukkanen, *University of Kuopio, Finland*  
 Pauliina Lehtolainen, *University of Kuopio, Finland*  
 Seppo Yia-herttua, *University of Kuopio, Finland*

1. Introduction
2. Vectors for Gene Transfer
  - 2.1. Non-viral Vectors
  - 2.2. Viral Vectors
    - 2.2.1. Adenoviral Vectors
    - 2.2.2. Retroviral and Lentiviral Vectors
    - 2.2.3. Adeno-associated Viral Vectors
    - 2.2.4. Other Viral Vectors
    - 2.2.5. Replicating Viral Vectors
3. Gene Delivery
  - 3.1. Ex Vivo Delivery
  - 3.2. In Vivo Delivery
  - 3.3. Pre-clinical Gene Therapy Experiments
4. Clinical Applications of Gene Therapy

**Tissue Engineering: Advances in Organ Replacement****271**

Kevin Shakesheff, *University of Nottingham, UK*  
 Andrew Lewis, *University of Nottingham, UK*  
 Lisa Riccalton-Banks, *RegenTec Ltd, UK*

1. Introduction
2. The Skin
3. The Liver
4. Kidney
  - 4.1. The Bioartificial Kidney

- 4.2. Tissue Engineering a Kidney
5. Bone
6. Blood Vessels
7. Skeletal Muscle
8. The Bladder
9. Nerve
10. Articular Cartilage
11. The Cornea

**The Nanostructure of the Nervous System and the Impact of Nanotechnology on Neuroscience 298**  
Gabriel A. Silva, *University of California, California*

1. Introduction
2. The Micro- and Nanoscale Structure of the Central Nervous System (CNS)
  - 2.1. The organization of the CNS
  - 2.2. The cellular and molecular structure of the CNS
  - 2.3. Membrane proteins and receptors
  - 2.4. Example of the nanoengineered CNS: Self-assembly of the presynaptic particle web
3. Synthetic and Engineering Methods in Nanotechnology
4. Applications of Nanoengineering and Nanotechnology to the CNS
  - 4.1. Applications to Basic Neuroscience
  - 4.2. Applications to Clinical Neuroscience
5. Challenges Associated with Nanotechnology Applications to the CNS
6. Conclusions
7. Acknowledgements

<b>Index</b>	<b>321</b>
<b>About EOLSS</b>	<b>329</b>